Skip to main content
. 2017 Oct;187(10):2273–2287. doi: 10.1016/j.ajpath.2017.06.009

Figure 6.

Figure 6

Olaratumab inhibits migration of HHSteCs in the absence of exogenous PDGF ligand, because of autocrine baseline signaling. A: Representative images from HHSteC transwell migration assays and quantification shows insignificant difference between no treatment (NT) and PDGF-BB treatment. B: Decreased HHSteC migration after olaratumab versus IgG-treated controls after 3 hours relative to IgG treatment and quantified. C: RT-PCR of cDNA derived from nontreated HHSteCs (left lane) shows baseline expression of PDGFA, PDGFB, PDGFC, and PDGFD compared to HHSteC RNA in the absence of reverse transcriptase (middle lane) or primer only control (right lane) (separated because of noninclusion of technical replicates). D: Representative Western blot shows PDGF-BB expression in nontreated HHSteC whole cell lysates and hepatocellular carcinoma (HCC) sample as a positive control. Ponceau staining is included as a loading control. E: Representative Western blots of PDGF ligands detected in concentrated baseline HHSteC media after 24 or 48 hours of serum starvation indicates autocrine secretion of PDGFB, PDGFC, and PDGFD, but not PDGFA. Concentrated supernatant from TGF-β1–activated HHSteCs is shown for comparison. ∗P < 0.05. Original magnification, ×50 (A and B).